Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors (original) (raw)

• Hottiger, M.O., Hassa, P.O., Lüscher, B., Schüler, H. & Koch-Nolte, F. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem. Sci. 35, 208–219 (2010).
  Article CAS Google Scholar
• Amé, J.C., Spenlehauer, C. & de Murcia, G. The PARP superfamily. Bioessays 26, 882–893 (2004).
  Article Google Scholar
• Sugimura, T., Fujimura, S., Hasegawa, S. & Kawamura, Y. Polymerization of the adenosine 5′-diphosphate ribose moiety of NAD by rat liver nuclear enzyme. Biochim. Biophys. Acta 138, 438–441 (1967).
  Article CAS Google Scholar
• Otto, H. et al. In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs). BMC Genomics 6, 139 (2005).
  Article Google Scholar
• Kleine, H. et al. Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation. Mol. Cell 32, 57–69 (2008).
  Article CAS Google Scholar
• Hassa, P.O. & Hottiger, M.O. The diverse biological roles of mammalian PARPs, a small but powerful family of poly-ADP-ribose polymerases. Front. Biosci. 13, 3046–3082 (2008).
  Article CAS Google Scholar
• Yélamos, J., Schreiber, V. & Dantzer, F. Toward specific functions of poly(ADP-ribose) polymerase-2. Trends Mol. Med. 14, 169–178 (2008).
  Article Google Scholar
• Calabrese, C.R. et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst. 96, 56–67 (2004).
  Article CAS Google Scholar
• Bryant, H.E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005).
  Article CAS Google Scholar
• Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).
  Article CAS Google Scholar
• Ashworth, A. Drug resistance caused by reversion mutation. Cancer Res. 68, 10021–10023 (2008).
  Article CAS Google Scholar
• Jagtap, P. & Szabo, C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discov. 4, 421–440 (2005).
  Article CAS Google Scholar
• Kauppinen, T.M. & Swanson, R.A. The role of poly(ADP-ribose) polymerase-1 in CNS disease. Neuroscience 145, 1267–1272 (2007).
  Article CAS Google Scholar
• Strosznajder, R.P., Czubowicz, K., Jesko, H. & Strosznajder, J.B. Poly(ADP-ribose) metabolism in brain and its role in ischemia pathology. Mol. Neurobiol. 41, 187–196 (2010).
  Article CAS Google Scholar
• Ba, X. & Garg, N.J. Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases. Am. J. Pathol. 178, 946–955 (2011).
  Article CAS Google Scholar
• Smith, S., Giriat, I., Schmitt, A. & de Lange, T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 282, 1484–1487 (1998).
  Article CAS Google Scholar
• McCabe, N. et al. Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. Oncogene 28, 1465–1470 (2009).
  Article CAS Google Scholar
• Huang, S.M. et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461, 614–620 (2009).
  Article CAS Google Scholar
• Purnell, M.R. & Whish, W.J. Novel inhibitors of poly(ADP-ribose) synthetase. Biochem. J. 185, 775–777 (1980).
  Article CAS Google Scholar
• Papeo, G. et al. Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity? Expert Opin Ther Pat 19, 1377–1400 (2009).
  Article CAS Google Scholar
• Fong, P.C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009).
  Article CAS Google Scholar
• Tutt, A. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235–244 (2010).
  Article CAS Google Scholar
• Carden, C.P., Yap, T.A. & Kaye, S.B. PARP inhibition: targeting the Achilles′ heel of DNA repair to treat germline and sporadic ovarian cancers. Curr. Opin. Oncol. 22, 473–480 (2010).
  Article CAS Google Scholar
• Frye, S.V. The art of the chemical probe. Nat. Chem. Biol. 6, 159–161 (2010).
  Article CAS Google Scholar
• Ruf, A., Mennissier de Murcia, J., de Murcia, G. & Schulz, G.E. Structure of the catalytic fragment of poly(AD-ribose) polymerase from chicken. Proc. Natl. Acad. Sci. USA 93, 7481–7485 (1996).
  Article CAS Google Scholar
• Bell, C.E. & Eisenberg, D. Crystal structure of diphtheria toxin bound to nicotinamide adenine dinucleotide. Biochemistry 35, 1137–1149 (1996).
  Article CAS Google Scholar
• Vedadi, M. et al. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc. Natl. Acad. Sci. USA 103, 15835–15840 (2006).
  Article CAS Google Scholar
• Niesen, F.H., Berglund, H. & Vedadi, M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2, 2212–2221 (2007).
  Article CAS Google Scholar
• Fedorov, O. et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl. Acad. Sci. USA 104, 20523–20528 (2007).
  Article CAS Google Scholar
• Plummer, R. Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. Clin. Cancer Res. 16, 4527–4531 (2010).
  Article CAS Google Scholar
• Pellicciari, R. et al. Towards new neuroprotective agents: design and synthesis of 4H-thieno[2,3-c] isoquinolin-5-one derivatives as potent PARP-1 inhibitors. Farmaco 58, 851–858 (2003).
  Article CAS Google Scholar
• Chiarugi, A. et al. Novel isoquinolinone-derived inhibitors of poly(ADP-ribose) polymerase-1: pharmacological characterization and neuroprotective effects in an in vitro model of cerebral ischemia. J. Pharmacol. Exp. Ther. 305, 943–949 (2003).
  Article CAS Google Scholar
• Hans, C.P. et al. Thieno[2,3-c]isoquinolin-5-one, a potent poly(ADP-ribose) polymerase inhibitor, promotes atherosclerotic plaque regression in high-fat diet-fed apolipoprotein E-deficient mice: effects on inflammatory markers and lipid content. J. Pharmacol. Exp. Ther. 329, 150–158 (2009).
  Article CAS Google Scholar
• Lehtiö, L. et al. Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J. Med. Chem. 52, 3108–3111 (2009).
  Article Google Scholar
• Karlberg, T. et al. Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor. J. Med. Chem. 53, 5352–5355 (2010).
  Article CAS Google Scholar
• Karlberg, T., Hammarström, M., Schütz, P., Svensson, L. & Schüler, H. Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888. Biochemistry 49, 1056–1058 (2010).
  Article CAS Google Scholar
• Lehtiö, L. et al. Zinc binding catalytic domain of human tankyrase 1. J. Mol. Biol. 379, 136–145 (2008).
  Article Google Scholar
• Iwashita, A. et al. Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors. FEBS Lett. 579, 1389–1393 (2005).
  Article CAS Google Scholar
• Yu, M. et al. PARP-10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase activity, inhibits transformation. Oncogene 24, 1982–1993 (2005).
  Article CAS Google Scholar
• Chou, H.Y., Chou, H.T. & Lee, S.C. CDK-dependent activation of poly(ADP-ribose) polymerase member 10 (PARP10). J. Biol. Chem. 281, 15201–15207 (2006).
  Article CAS Google Scholar
• Citarelli, M., Teotia, S. & Lamb, R.S. Evolutionary history of the poly(ADP-ribose) polymerase gene family in eukaryotes. BMC Evol. Biol. 10, 308 (2010).
  Article Google Scholar
• Edwards, A.M. et al. Too many roads not taken. Nature 470, 163–165 (2011).
  Article CAS Google Scholar
• Ringner, M. What is principal component analysis? Nat. Biotechnol. 26, 303–304 (2008).
  Article CAS Google Scholar